Adaptin Bio (APTN) EBITDA (2023 - 2026)
Adaptin Bio (APTN) posted EBITDA of -$1.1 million for Q1 2026, up 16.36% sequentially from -$1.4 million in Q4 2025, and down 34.53% YoY from -$1.7 million in Q1 2025.
Adaptin Bio (APTN) EBITDA (2023 - 2026) Analysis & Trends
Adaptin Bio has reported EBITDA for 4 years, with the latest figure at -$1.1 million in Q1 2026.
- Quarterly EBITDA fell 34.53% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.7 million (down 82.93% YoY) and the FY2025 annual result came in at -$5.4 million, down 110.71% from the prior year.
- EBITDA improved to -$1.1 million in Q1 2026 per APTN's latest filing, from -$1.4 million in the prior quarter.
- Over five years, EBITDA peaked at -$34155.0 in Q4 2023 and troughed at -$1.7 million in Q3 2025.
- A 4-year average of -$836915.8 and a median of -$850458.0 in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2024 and 2026: EBITDA sank 2216.71% in 2024, then sank 34.53% in 2026.
- Over 4 years, EBITDA stood at -$34155.0 in 2023, then slumped by 1387.57% to -$508080.0 in 2024, then slumped by 169.25% to -$1.4 million in 2025, then increased by 16.36% to -$1.1 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$1.1 million, -$1.4 million, and -$1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.20 Mn |
| Mar 31, 2026 | -1.14 Mn |
| Dec 31, 2025 | -1.37 Mn |
| Sep 30, 2025 | -1.68 Mn |
| Jun 30, 2025 | -1.52 Mn |
| Mar 31, 2025 | -850,458.00 |
| Dec 31, 2024 | -508,080.00 |
| Sep 30, 2024 | -994,749.00 |
| Jun 30, 2024 | -767,320.00 |
| Mar 31, 2024 | -299,736.00 |
| Dec 31, 2023 | -34,155.00 |
| Sep 30, 2023 | -42,938.00 |